FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and pharmaceutics, and concerns a method of treating pleural mesothelioma by administering a conjugate containing a targeting peptide containing a NGR motif, and cytokine representing TNF specified in a group consisting of TNFα, TNFβ, and also refers to a pharmaceutical formulation containing the above conjugate dissolved in suitable buffers.
EFFECT: group of inventions provides the therapeutic effectiveness, relative safety and low toxicity profile for the patients.
9 cl, 2 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPY OF METASTATIC UROTHELIAL CANCER USING ANTIBODY-DRUG CONJUGATE SATSITUZUMAB GOVITECAN (IMMU-132) | 2017 |
|
RU2757395C2 |
| METHODS AND COMPOSITIONS FOR CAR-T-CELL THERAPY | 2017 |
|
RU2792653C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
| DEVICES AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY | 2018 |
|
RU2795984C2 |
| CEREBRAL CANCER TREATMENT WITH ONCOLYTIC ADENOVIRUS | 2014 |
|
RU2689553C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA | 2014 |
|
RU2679806C2 |
| COMPOSITIONS OF CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSES AND USES THEREOF IN CANCER TREATMENT | 2014 |
|
RU2666141C2 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
| TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER CHARACTERIZED BY Trop-2 EXPRESSION USING SATSITUZUMAB GOVITECAN AND Rad51 INHIBITOR | 2018 |
|
RU2758234C2 |
